| Date |
Event |
Presentation |
Speakers |
|
February 6, 2011
|
5th Drug Discovery for Neurodegeneration: An Intensive Course for Translating Research into Drugs
|
Academic Models of Drug Discovery Services & Utilizing CROs
|
Marcie Glicksman
|
|
October 13, 2010
|
Making the Right Investments in Biomedical Informatics for Drug Development and Healthcare
|
Meaningful Use and HIT Architectures for Health Care Innovation and Transformation
|
Kenneth D Mandl
|
|
|
|
Transformational capability of biomedicalinformatics to change the way we do clinical R&D and deliver health care.
|
Richard Platt
|
|
|
|
THEME B - Policy of Biomedical Informatics in Health Care and Pharma: FDAAA: Sentinel Initiative
|
Richard Platt
|
|
September 27, 2010
|
25th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis: from Bench to Bedside to Biomarkers
|
Opening Remarks
|
Rakesh K Jain
|
|
|
|
Tumor Microenvironment I: Angiogenesis and Vascular Transport
|
Rakesh K Jain
|
|
|
|
Normalization of Tumor Vasculature and Microenvironment by Antiangiogenic Therapy: from Bench to Bedside to Biomarkers
|
Rakesh K Jain
|
|
|
|
Tumor Microenvironment II: Interstitial and Lymphatic Transport
|
Rakesh K Jain
|
|
|
|
Tumor Stroma Generation: Role of VPF/VEGF
|
Harold F. Dvorak
|
|
|
|
Mining the Human Proteome: Biomarker Discovery for Human Cancer and Its Metastases
|
Marsha Moses
|
|
|
|
Genetics in Cancer Therapy
|
Raju Kucherlapati
|
|
|
|
Imaging Angiogenesis and Vascular Function in Cancer Patients
|
A. Gregory Sorensen
|
|
August 23, 2010
|
The Ubiquitin Drug Discovery & Diagnostics Conference
|
Proteomic and informatic approaches in the study of the Ubiquitin Pathway
|
Wade Harper
|
|
|
|
Keynote Address
|
Alfred L. Goldberg
|
|
|
|
Inhibition of proteasomal deubiquitinating enzyme Usp14
|
Daniel Finley
|
|
|
|
Targeting Protein Degradatation as a Therapeutic Strategy in Myeloma
|
Kenneth C Anderson
|
|
July 11, 2010
|
Translational Cancer Medicine 2010 (USA)
|
Drugging “undruggable” transcriptional targets
|
Gregory L Verdine
|
|
|
|
Novel strategies for drug development in oncology
|
D. Gary Gilliland
|
|
|
|
Comprehensive genomic approaches to identify cancer targets
|
William C Hahn
|
|
|
|
Modeling drug sensitivity and resistance in human tumor-derived cell lines
|
Jeffrey Settleman
|
|
|
|
Functionalizing the cancer genome
|
Lynda Chin
|
|
|
|
Title to be announced
|
Levi A Garraway
|
|
|
|
Altered nutrient requirements in cells with activated mTOR complex 1
|
John Blenis
|
|
|
|
Title to be announced
|
Shyamala Maheswaran
|
|
|
|
Title to be announced
|
George Daniel Demetri
|
|
July 11, 2010
|
3rd International Congress On Stem Cells And Tissue Formation
|
Biomaterials for Cell Transplantation and Drug Delivery | Amy Brock
|
Amy Brock
|
|
|
|
Programming Cells In Vivo Using Polymers
|
David J. Mooney
|
|
June 23, 2010
|
Structure-Based Drug Design
|
In Silico Discovery of Small Molecule Transcription Factor Inhibitors
|
Alan C Rigby
|
|
|
|
Chairperson’s Remarks
|
Alan C Rigby
|
|
May 19, 2010
|
Towards Personalized Cancer Medicine
|
New Cancer Targets Emerging From Studies of the von Hippel-Lindau Tumor Suppressor Protein
|
William G Kaelin
|
|
|
|
Functionalizing the Cancer Genome
|
Lynda Chin
|
|
|
|
SESSION III: Oncogenomics and Tumor Profiling
|
Lynda Chin
|
|
|
|
Target and Drug Discovery in Oncology: The Right Drug for the Right Patient
|
D. Gary Gilliland
|
|
|
|
PANEL DISCUSSION
|
Lynda Chin
|
|
April 6, 2010
|
IBCs 5th Annual China 2010 Pharmaceutical R&D Summit
|
China's Healthcare Reform: Implications for the Industrial Sectors
|
Yuan-Li Liu
|
|
February 1, 2010
|
4th DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE
|
Session Overview
|
Marcie Glicksman
|
|
|
|
II. In-vitro Testing: Early Phases of Drug Discovery
|
Marcie Glicksman
|
|
|
|
Stem Cells to Accelerate Drug Discovery for Neurodegenerative Disease
|
Lee Rubin
|
|
|
|
Developing Relevant High-Throughput Assays for the Identification of Potential Drug Candidates
|
Marcie Glicksman
|
|
|
|
Track 1: Target Validation to Lead Optimization AD Case Study
|
Marcie Glicksman
|
|
January 22, 2010
|
2010 Gastrointestinal Cancers Symposium
|
General Session IV: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract: Prevention, Screening, and Diagnosis
|
Sapna Syngal
|
|
|
|
Normalizing the Tumor Microenvironment to Improve Drug Delivery and Efficacy
|
Rakesh K Jain
|
|
|
|
Newer Radiation Techniques in the Treatment of Hepatobiliary and Pancreatic Cancers
|
Harvey J. Mamon
|
|
|
|
Advanced Imaging Techniques
|
Dushyant Sahani
|
|
|
|
Gastroenterologist
|
William R. Brugge
|
|
|
|
Advanced Imaging Techniques
|
Dushyant Sahani
|
|
November 2, 2009
|
Track 3: Fourth Annual Ion Channels as Therapeutic Targets
|
Structural Insights into the Function of TRPV Channels
|
Rachelle Gaudet
|
|
|
|
Ion Channel Drug Targets
|
David E. Clapham
|
|
September 24, 2009
|
Track 3:Advancing Cancer Therapy : Inaugural Circulating Tumor Cells
|
Genome-Subtractive Cancer-Specific Blood Assay
|
Amin L Kassis
|
|
September 23, 2009
|
Track 3: Advancing Cancer Therapy : Second Annual Translational Cancer Medicine
|
The Use of Genetically Engineered Mice for Preclinical Testing of Novel Cancer Therapeutics
|
Kwok-Kin Wong
|
|
September 19, 2009
|
Nature Chemical Biology Symposium 2009: Chemical Biology in Drug Discovery
|
The chemical biology of behavior and psychiatric disease
|
Randall Peterson
|
|
|
|
Drugging the "undruggable"
|
Gregory Verdine
|
|
August 5, 2009
|
New Frontiers in Cancer Drug Development
|
A New Paradigm for Translational Cancer Research: Targeting Endocrine Factors and Real Human Tumors
|
Sandra S. McAllister
|
|
|
|
Turning Cancer Sequencing Data into Therapeutic Targets
|
Heidi Greulich
|
|
|
|
Combinations of Novel and Conventional Cancer Agents: Challenges and Opportunities
|
Kenneth C Anderson
|
|
|
|
The Use of Genetically Engineered Mouse Lung Cancer Models to Assess Effectiveness of Targeted Therapeutic Combinations
|
Kwok-Kin Wong
|
|
|
|
The Evolving Treatment Paradigm in Multiple Myeloma
|
Kenneth C Anderson
|
|
August 5, 2009
|
Targets in Context - Linking Targets to Diseases Agenda
|
Michael Foley, Ph.D. Build-Couple-Pair Strategy for Diversity-Oriented Synthesis Yields a Unique Compound Collection for Probe Development and Drug Discovery
|
Michael Foley
|
|
|
|
In Vivo Chemical Screening in Zebrafish
|
Joanna Yeh
|
|
June 8, 2009
|
RNAi for Functional Screens
|
Talk Title to Be Announced
|
Caroline Shamu
|
|
April 22, 2009
|
PI 3-Kinase Signaling in Disease (Z3)
|
PI 3-Kinase Signaling and Cancer
|
Jeffrey Adam Engelman, Pier Paolo
|
|
February 24, 2009
|
11th National Conference on Managing Legal Risks in Structuring & Conducting Clinical Trials
|
Instituting Policies to Expedite Medicare Approval for Clinical Trial Costs and Expenses
|
Douglass Reichgott
|
|
February 8, 2009
|
CHEMISTRY IN CANCER RESEARCH: A Vital Partnership in Cancer Drug Discovery and Development
|
Keynote Lectures
|
Gregory L Verdine
|
|
|
|
Session 4: Chemistry in Support of Lead Discovery/Chemoinformatics
|
Alan C Rigby
|
|
January 26, 2009
|
7th Annual Partnering with Central Labs
|
Track A : Central Lab Cost Drivers and Logistics Discussion Forum
|
David Mooney
|
|
January 5, 2009
|
High Content Analysis
|
Multi-Color Live Cell Immunofluorescence Timecourse Analysis of Human-Induced Pluripotent Stem Cell Formation
|
Thorsten M Schlaeger
|
|
December 4, 2008
|
BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008)
|
TBD
|
Yu-Li Wang
|
|
|
|
Co-Chair :Track 2-8
|
Zhen Y. Jiang
|
|
|
|
Analyzing Insulin Signaling Networks and Metabolic Functions Using Quantitative Proteomics Approach :Track 2-8
|
Zhen Y. Jiang
|
|
|
|
Oral Delivery of Glucan Encapsulated siRNA to Macrophages Targeting Map4K4 Attenuates Systemic Inflammation :Track 2-8
|
Myriam Aouadi
|
|
|
|
Developmental Origin of Adipose Tissue: Novel Role of Bone Morphogenetic Proteins in Adipogenesis and Energy Metabolism :Track 2-8
|
Yu-Hua Tseng
|
|
|
|
Title: TBD : Track 4-4
|
Jing X. Kang
|
|
November 12, 2008
|
Third Annual Post-Approval Drug Safety Strategies: Best Practices to Mitigate Risks throughout the Product's Life Cycle
|
Establishing Best Practices in Evaluating, Planning and Executing “Fit-for-Purpose” Benefit/Risk Management Programs for the 21st Century
|
Bjorn Olsen
|
|
November 3, 2008
|
ASAP-CHI Bio-Pharma Alliance Summit
|
High Performing Collaborative Research Teams: Lessons from the Harvard Stem Cell Institute
|
Brock Reeve
|
|
October 12, 2008
|
15th North American Regional Meeting - International Society for the Study of Xenobiotics
|
Resolvins and Protectins : Anti-inflammatory and Pro-resolving Actions of Omega-3 Fatty Acid-derived Mediators
|
Matthew Spite
|
|
August 19, 2008
|
Enabling Point-of-Care Diagnostics
|
Leveraging Cell Phone Technology to Make Point-of-Care Diagnostics Accessible in the Developing World
|
Boris Nikolic
|
|
August 11, 2008
|
CELLutions SUMMIT
|
Programming Cells in Situ
|
David Mooney
|
|
|
|
Developing Stem Cell-Based Therapies for Cancer
|
Khalid Shah
|
|
July 19, 2008
|
22nd Annual Symposium of The Protein Society
|
Concurrent Morning Symposia 2: Proteomics [sponsored by Merck Research Laboratories]
|
Claude Lechene
|
|
|
|
Concurrent Morning Symposia 12: Systems Biology
|
Josh LaBaer
|
|
June 18, 2008
|
Accelerating Anticancer Agent Development and Validation Workshop
|
Proof of Concept to Pre-Clinical Scientist
|
George Daniel Demetri
|
|
May 30, 2008
|
ASCO Annual'08 Meeting
|
breast cancer-- Adjuvant Chemotherapy of Breast Cancer: Do We Still Need Anthracyclines?
|
Eric P. Winer
|
|
|
|
breast cancer-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A)
|
Judy E Garber
|
|
|
|
breast cancer-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B)
|
Judy E Garber
|
|
|
|
cancer genetics-- Molecular Pathways of Cancer Predisposition in Children, Adolescents, and Young Adults
|
Lisa Diller
|
|
|
|
cancer genetics-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A)
|
Judy E Garber
|
|
|
|
cancer genetics-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B)
|
Judy E Garber
|
|
|
|
cancer prevention/epidemiology-- Molecular Pathways of Cancer Predisposition in Children, Adolescents, and Young Adults
|
Lisa Diller
|
|
|
|
cancer prevention/epidemiology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A)
|
Judy E Garber
|
|
|
|
cancer prevention/epidemiology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B)
|
Judy E Garber
|
|
|
|
central nervous system tumors-- Managing the Medical Complications of Patients with Brain Tumors (CPO10A)
|
Patrick Y. Wen
|
|
|
|
central nervous system tumors-- Managing the Medical Complications of Patients with Brain Tumors (CPO10B)
|
Patrick Y. Wen
|
|
|
|
clinical trials-- Early Data: Presenting and Publishing Preliminary Results
|
Donna S. Neuberg
|
|
|
|
ethics-- Early Data: Presenting and Publishing Preliminary Results
|
Donna S. Neuberg
|
|
|
|
gastrointestinal (noncolorectal) cancer-- Gastrointestinal Stromal Tumor (GIST) Comes of Age: Current Management Using Molecular Pathology, Surgery, and Targeted Therapy
|
George Daniel Demetri
|
|
|
|
geriatric oncology--Adjuvant Chemotherapy of Breast Cancer: Do We Still Need Anthracyclines?
|
Eric P. Winer
|
|
|
|
lung cancer-- Targeted and Novel Agents in Small Cell Lung Cancer
|
Bruce E. Johnson
|
|
|
|
melanoma/skin cancers-- Melanoma in Children, Adolescents, and Young Adults
|
David E Fisher
|
|
|
|
patient and survivor care-- Managing the Medical Complications of Patients with Brain Tumors (CPO10A)
|
Patrick Y. Wen
|
|
|
|
patient and survivor care-- New Models for Survivorship Care Programs (M15)
|
Lawrence N. Shulman
|
|
|
|
patient and survivor care-- Treatment Approaches and Functional Outcomes in Pediatric Sarcomas
|
Mark Gebhardt
|
|
|
|
patient and survivor care-- Managing the Medical Complications of Patients with Brain Tumors (CPO10B)
|
Patrick Y. Wen
|
|
|
|
pediatric cancer-- Molecular Pathways of Cancer Predisposition in Children, Adolescents, and Young Adults
|
Lisa Diller
|
|
|
|
pediatric cancer-- Challenges and Optimizing Outcomes in Adolescents and Young Adults with Cancer
|
Karen H. Albritton
|
|
|
|
pediatric cancer-- Treatment Approaches and Functional Outcomes in Pediatric Sarcomas
|
Mark Gebhardt
|
|
|
|
pediatric cancer-- Melanoma in Children, Adolescents, and Young Adults
|
David E Fisher
|
|
|
|
sarcoma/bone and soft tissue cancers-- Predicting and Targeting Drug Resistance to Tyrosine Kinase Inhibitors
|
Jeffrey Adam Engelman
|
|
|
|
sarcoma/bone and soft tissue cancers-- Treatment Approaches and Functional Outcomes in Pediatric Sarcomas
|
Mark Gebhardt
|
|
|
|
tumor biology-- Predicting and Targeting Drug Resistance to Tyrosine Kinase Inhibitors
|
Jeffrey Adam Engelman
|
|
|
|
meet the professor sessions-- New Models for Survivorship Care Programs (M15)
|
Lawrence N. Shulman
|
|
|
|
clinical problems in oncology-- Managing the Medical Complications of Patients with Brain Tumors (CPO10A)
|
Patrick Y. Wen
|
|
|
|
clinical problems in oncology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14A)
|
Judy E Garber
|
|
|
|
clinical problems in oncology-- Recognition and Management of Patients with Inherited Risk of Breast Cancer (CPO14B)
|
Judy E Garber
|
|
|
|
clinical problems in oncology-- Managing the Medical Complications of Patients with Brain Tumors (CPO10B)
|
Patrick Y. Wen
|
|
May 18, 2008
|
MAGI’s 2008 Clinical Trial Agreements, Budgets & Regulatory Conference – EAST
|
Track B: Budgets Medicare Reimbursement for Clinical Trials
|
Douglass Reichgott
|
|
May 18, 2008
|
G Protein-Coupled Receptors: New Insights in Functional Regulation and Clinical Application (E2)
|
GPCRs in Physiology 2
|
Jean-Pierre Vilardaga
|
|
April 28, 2008
|
Clinical Development of Therapeutic Antibodies
|
Normalizing Tumor Vessels and Microenvironment to Treat Cancer: From the Bench to Bedside and Back
|
Rakesh K Jain
|
|
March 30, 2008
|
Metabolic Pathways of Longevity
|
Longevity and Insulin/IGF-I Signaling in Rodents
|
C. Ronald Kahn
|
|
|
|
The Role of Nutrient Sensing in Aging II: Caloric Restriction
|
David A Sinclair, Pere Puigserver
|
|
|
|
Oxidative Stress, Aging, & Insulin/IGF1 Signaling
|
Evan Rosen
|
|
|
|
Mitochondria Dysfunction, Aging, & Insulin/IGF1
|
Vamsi K Mootha
|
|
March 30, 2008
|
Nuclear Receptors: Steroid Sisters
|
Steroid Receptors and Chromatin
|
Myles Brown
|
|
|
|
Analyses of Nuclear Receptor-Dependent Transcription (Joint)
|
Myles Brown
|
|
|
|
Workshop 3 - Hot Topics: Chromatin/Transcription
|
Mathieu Lupien
|
|
|
|
Steroid Receptor Biology
|
Inna I. Astapova
|
|
|
|
Mechanisms of Receptor Action
|
Pere Puigserver
|
|
|
|
Nuclear Receptor Biology (Joint)
|
Bruce Spiegelman
|
|
March 30, 2008
|
Nuclear Receptors: Orphan Brothers
|
Steroid Receptors and Chromatin
|
Myles Brown
|
|
|
|
Analyses of Nuclear Receptor-Dependent Transcription (Joint)
|
Myles Brown
|
|
|
|
Workshop 3 - Hot Topics: Chromatin/Transcription
|
Mathieu Lupien
|
|
|
|
Mechanisms of Receptor Action
|
Pere Puigserver
|
|
|
|
Steroid Receptor Biology
|
Inna I. Astapova
|
|
|
|
Nuclear Receptor Biology (Joint)
|
Bruce Spiegelman
|
|
March 25, 2008
|
2008 BIOPHARMA OUTSOURCING
|
Identifying the Right CRO and Shepherding a Product in Preclinical
|
Judith K Gwathmey
|
|
March 16, 2008
|
Advances in Cancer Research: From the Laboratory to the Clinic
|
Title to be announced
|
William G Kaelin
|
|
|
|
Clinical Targeting and Inhibition of Tyrosine Kinases in GIST and Sarcomas: Lessons for Cancer Therapy and Future Directions
|
George Daniel Demetri
|
|
|
|
RNAi, NON-CODING RNA, AND microRNA
|
William C Hahn
|
|
|
|
Functional Genomics, Experimental Models, and Cancer
|
William C Hahn
|
|
December 1, 2007
|
47TH American Socieity of Cell Biology
|
Design Principles for Connecting the Genome to the World
|
I Philips, C. Ajo-Franklin
|
|
|
|
Minisymposium 1A:Cell Biology Working Group: Challenges in Cell Biology—The Nature of Cytoplasm
|
Timothy J Mitchison
|
|
|
|
Interphase and Mitotic CDKs Follow Kinetically Distinct Paths to Activation in Human Cells.
|
C. Zhang
|
|
|
|
*Single-Molecule Analysis Reveals the Distribution of Potential vs. Active DNA Replication Origins in Human Cells
|
R. Lebofsky
|
|
|
|
Cell Matrix Interactions (Room 140A)
|
Yu-Li Wang
|
|
|
|
Advances in Bone Cell Molecular Biology: Epigenetic Control
|
Jane Lian, Gary S Stein
|
|
|
|
CLASPs Clutching Microtubule Networks (Room 209 B/C)
|
David Van Vactor
|
|
|
|
At the Limits: Optical Methods for Single Molecules, Cells, and Organisms
|
Jennifer Waters, Samara Rech-Peterson
|
|
|
|
High Performance Image Analysis and Photomanipulative Techniques for
|
Jeffrey Nickerson
|
|
|
|
Building the Cell (Room 140B)
|
L Mahadevan
|
|
|
|
Systems Biology of Receptor Tyrosine Kinase Networks (Room 206)
|
Peter K. Sorger
|
|
|
|
Public Service Award Presentation
|
Matthew Michael
|
|
|
|
Primary Role for Centrosome Proteins in Cilia Formation and Cilia-associated Disorders
|
B Delaval, L Covassin Barberis, N Lawson, Stephen J Doxsey
|
|
|
|
Cell-Type Variation in Responses to Anti-mitotic Drugs.
|
C Loy, J Orth, C Shamu, M Tsui, V Yanamadala, Timothy J Mitchison
|
|
|
|
Fluorescence Correlation Spectroscopy Workshop
|
Daniel Needham
|
|
|
|
Actin Disassembly by Whole-Filament Destabilization.v
|
H Kueh, W M Brieher, Timothy J Mitchison
|
|
|
|
How Does Thrombospondin Induce CNS Synaptogenesis?
|
J. T. Lawler
|
|
|
|
Identifying Matrix- and Growth Factor-induced Transcriptional Dichotomies by Stochastic Sampling.
|
K A Janes, Joan Brugge
|
|
|
|
High-Tech Cell Biology
|
Kendall Knight
|
|
|
|
DNA Damage Signaling Events Revealed by 4Pi Microscopy.
|
Kendall Knight, Brian T Bennett
|
|
|
|
Novel Microscopy Methodology to Examine DNA Damage Signaling and Repair.
|
Brian T Bennett
|
|
|
|
Heterochromatin Formation in Fission Yeast.
|
M Huarte, Yang Shi
|
|
|
|
Anti-fi brotic Property of CTGF siRNA in the Liver via Targeted Delivery to Hepatic Stellate Cells.
|
David Roger Brigstock, C Lawrencia
|
|
|
|
Mallory Body Formation in the Livers of Drug-primed Mice Is Regulated by an Epigenetic Mechanism
|
Jian Li
|
|
|
|
Myosin-activated Random Stress Fluctuations in the Actin Cytoskeleton
|
David Weitz
|
|
|
|
Cytoplasmic Dynein Is a Better Navigator than Kinesin on Tau-decorated Microtubules.
|
J. L. Ross
|
|
|
|
Determining the Molecular Architectures of Cellular Machines by Satisfaction of Spatial Restraints: The Nuclear Pore Complex.
|
Adrian Salic
|
|
|
|
Posters Displayed:Monday
|
Joan Brugge
|
|
|
|
Amaxa GmbH:
|
Alan D Andrea
|
|
|
|
Post-Cytokinetic DNA Segregation by ATPases That Form DNA-Conducting Channels
|
Tom A Rapoport, N L Sullivan, K Marquis
|
|
|
|
Maintenance of Polarity and Cell Shape in Vibrio cholerae
|
Matthew K Waldor
|
|
|
|
Biochemical Characterization of Type III-secreted Bacterial Acetyltransferases
|
J Orth
|
|
November 7, 2007
|
Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13)
|
Session 11: Anti-Infectious Drug Discovery & Development (II) (09:00-12:20)
|
Irene Bosch
|
|
|
|
Session 11: Identification of Novel and Effective Antiviral Treatment and zstablishment of Disease Pathogenesis: A journey of Global Gene Expression of dengue virus infection (11:20-11:40)
|
Irene Bosch
|
|
November 4, 2007
|
AACR Centennial Conference: Translational Cancer Medicine
|
Plenary Session 2: Proteomics, Genomics and Biomarker Discovery
|
Gregory L Verdine
|
|
|
|
Plenary Session 6: Clinical Intervention and Populations Outcomes: Global Strategies
|
Rakesh K Jain
|
|
October 25, 2007
|
Pain Therapeutics Summit 2007
|
Workshop concludes / Conference registration begins
|
David Borsook
|
|
October 17, 2007
|
Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18)
|
TARGETING PAIN MANAGEMENT: TRP Channels as Drug Targets (14:30-15:00)
|
David E. Clapham
|
|
October 16, 2007
|
Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17)
|
RNAi as a Predictive Tool (14:20-15:25)
|
Yaakov Benenson
|
|
|
|
RNAi as a Predictive Tool: RNAi-Based Molecular Logic Circuits (14:55-15:25)
|
Yaakov Benenson
|
|
|
|
RNAi FOR IN VIVO TARGET VALIDATION (16:30-19:30)
|
Anna Moore
|
|
|
|
RNAi FOR IN VIVO TARGET VALIDATION: In Vivo Imaging of siRNA Delivery and Silencing in Tumors (17:00-17:30)
|
Anna Moore
|
How We Rank